IceCure Medical (NASDAQ:ICCM – Get Free Report) and Bausch + Lomb (NYSE:BLCO – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.
Risk & Volatility
IceCure Medical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Institutional and Insider Ownership
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 1.4% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares IceCure Medical and Bausch + Lomb”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.38 million | 0.83 | -$15.06 million | ($8.52) | -0.10 |
| Bausch + Lomb | $5.10 billion | 1.46 | -$360.00 million | ($0.31) | -67.42 |
IceCure Medical has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares IceCure Medical and Bausch + Lomb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
| Bausch + Lomb | -2.05% | 5.01% | 2.34% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for IceCure Medical and Bausch + Lomb, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 1 | 1 | 2 | 0 | 2.25 |
| Bausch + Lomb | 1 | 8 | 4 | 2 | 2.47 |
IceCure Medical currently has a consensus price target of $30.00, suggesting a potential upside of 3,547.86%. Bausch + Lomb has a consensus price target of $20.83, suggesting a potential downside of 0.32%. Given IceCure Medical’s higher probable upside, research analysts plainly believe IceCure Medical is more favorable than Bausch + Lomb.
Summary
Bausch + Lomb beats IceCure Medical on 10 of the 14 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
